HomeAbout

TL;DR CNBC


Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know - TL;DR CNBC

Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know

Publishing timestamp: 2023-07-08 07:00:01


Summary

Medicare will now cover the Alzheimer's treatment Leqembi, which is the only drug on the market that has shown the ability to slow the progression of the disease in clinical trials. However, patients may still face high out-of-pocket costs, which could be unaffordable for many, especially Black and Hispanic patients who are at higher risk of Alzheimer's. The article discusses the pricing of Leqembi, Medicare coverage, eligibility requirements, and the risks associated with the treatment.


Sentiment: MIXED

Tickers: 4523.T-JPBIIB

Keywords: medicare health plansbiotech and pharmaceuticalshealth care industryalzheimer's diseaseu.s. economybiotechnologybusiness newspoliticssocial issueseisai co ltdbreaking news: businesssciencebiogen incbusiness

Source: https://www.cnbc.com/2023/07/08/leqembi-and-medicare-what-patients-and-doctors-should-know.html


Developed by Leo Phan